āļ§ัāļ™āļžุāļ˜āļ—ี่ 29 āļ•ุāļĨāļēāļ„āļĄ āļž.āļĻ. 2568

Complement system

Complement system


ðŸ§Đ āļ āļēāļžāļĢāļ§āļĄ: “āļĢāļ°āļšāļšāđ€āļŠāļĢิāļĄāļ ูāļĄิāļ„ุ้āļĄāļัāļ™” āļ„ืāļ­āļ­āļ°āđ„āļĢ

Complement system āļ„ืāļ­āļĢāļ°āļšāļšāđ‚āļ›āļĢāļ•ีāļ™āļāļ§่āļē 30 āļŠāļ™ิāļ”āļ—ี่āļŦāļĄุāļ™āđ€āļ§ีāļĒāļ™āļ­āļĒู่āđƒāļ™āļžāļĨāļēāļŠāļĄāļēāđāļĨāļ°āļšāļ™āđ€āļĒื่āļ­āđ€āļ‹āļĨāļĨ์ āđ€āļ›็āļ™āļāļĨāđ„āļ “āļ†่āļēāđ€āļŠื้āļ­āļ­ัāļ•āđ‚āļ™āļĄัāļ•ิ” āļ‚āļ­āļ‡āļĢ่āļēāļ‡āļāļēāļĒ āļ­āļĒู่āļ•āļĢāļ‡āļāļĨāļēāļ‡āļĢāļ°āļŦāļ§่āļēāļ‡ āļ ูāļĄิāļ„ุ้āļĄāļัāļ™āđāļ•่āļāļģāđ€āļ™ิāļ” (innate) āđāļĨāļ° āļ ูāļĄิāļ„ุ้āļĄāļัāļ™āđāļšāļšāļˆāļģāđ€āļžāļēāļ° (adaptive)

āļŦāļ™้āļēāļ—ี่āļŦāļĨัāļ

1.       Opsonization (C3b)āđ€āļ„āļĨืāļ­āļšāļœิāļ§āđ€āļŠื้āļ­āđ‚āļĢāļ„āđƒāļŦ้ phagocyte āļˆัāļšāļิāļ™āļ‡่āļēāļĒ

2.       Inflammation (C3a, C5a)āļāļĢāļ°āļ•ุ้āļ™āļŦāļĨāļ­āļ”āđ€āļĨืāļ­āļ”āļ‚āļĒāļēāļĒāļ•ัāļ§ āļ”ึāļ‡āđ€āļĄ็āļ”āđ€āļĨืāļ­āļ”āļ‚āļēāļ§āļĄāļēāļšāļĢิāđ€āļ§āļ“āļ•ิāļ”āđ€āļŠื้āļ­

3.       Cytolysis (C5b–C9; MAC (membrane attack complex))āđ€āļˆāļēāļ°āļĢูāđ€āļĒื่āļ­āļŦุ้āļĄāđ€āļŠื้āļ­āđ‚āļĢāļ„āđƒāļŦ้āđāļ•āļ

4.       Clear immune complex / apoptotic cellsāļāļģāļˆัāļ”āđ€āļĻāļĐāđ€āļ‹āļĨāļĨ์āđāļĨāļ° immune complex

5.       āļŠ่āļ§āļĒ adaptive immunityāļāļĢāļ°āļ•ุ้āļ™ B cell āđāļĨāļ° antigen presentation


The complement cascade pathways. The classical pathway is initiated by binding of C1q to antibody chains triggering the activation of C1s and C1r. The activated C1 complex cleaves circulating C2 and C4 molecules into active C2a, C2b and C4a, C4b molecules leading to the formation of the C3 convertase following binding of the active C2b to C4b (C4b2b). The lectin pathway is triggered by recognition of microbial carbohydrates by ficolins, mannan binding lectin (MBL), or collectins which bind to mannan binding lectin serine peptidases (MASPs) forming a complex. The activated MASPs also lead to cleavage of C2 and C4 into active C2a, C2b and C4a, C4b fragments and thus the formation of the C3 convertase (C4b2b). The alternative pathway is triggered by spontaneous C3 activation by C3 hydrolysis which in the presence of Factor B and Factor D leads to the formation of a fluid phase C3 convertase through binding of the hydrolysed C3 to an active Bb fragment (C3(H2O)Bb. C3(H2O)Bb has the ability to cleave C3 into active C3a and C3b fragments. Binding of C3b to Bb results in the formation of the C3 convertase of the alternative pathway (C3bBb). All three pathways converge at the C3 step in order for the cascade to proceed further to the formation of the C5 convertase by binding of an active C3b molecule to the existing C3 convertases which results in their conversion into active C5 convertases (C4b2bC3b, C3bBbC3b). The C5 convertases cleave circulating C5 molecules into active C5a and C5b molecules allowing binding of C5b to the cell membrane and its assembly with C6, C7 and C8 molecules in order to polymerize C9 molecules and eventually form C5b-9, also known as the membrane attack complex (MAC). Formation of sufficient MAC molecules on the cell membrane ultimately leads to lysis while simultaneous release of C3a and C5a anaphylatoxins and their binding to respective cellular receptors C3aR and C5aR1, will allow for initiation of cellular activation and chemotaxis promoting a strong inflammatory state. The presence of complement regulatory proteins (CRPs), cell bound (CD55, CD46, CD59, CR1) or circulating (C4b binding protein, Factor H, vitronectin, clusterin) prevent overactivation of the complement cascade pathways and dysregulation of the complement system

⚙️ āđ€āļ›āļĢีāļĒāļšāđ€āļ—ีāļĒāļš 3 āđ€āļŠ้āļ™āļ—āļēāļ‡āļŦāļĨัāļ

āļĨัāļāļĐāļ“āļ°

Classical pathway

Lectin pathway

Alternative pathway

āļŠิ่āļ‡āļ—ี่āļāļĢāļ°āļ•ุ้āļ™

Antibody (IgM, IgG1, IgG3) āļˆัāļš antigen

Lectin (MBL, ficolin) āļˆัāļšāļ™้āļģāļ•āļēāļĨāļšāļ™āļœิāļ§āđ€āļŠื้āļ­

C3 “tickover” autoactivation

Complex āđ€āļĢิ่āļĄāļ•้āļ™

C1 (C1q, C1r, C1s)

MBL + MASP (MBL-associated serine protease)

C3b + Factor B + Factor D + Properdin

C3 convertase

C4b2b

C4b2b (āđ€āļŦāļĄืāļ­āļ™ classical)

C3bBb (stabilized by Properdin)

C5 convertase

C4b2b3b

C4b2b3b

C3bBbC3b

āļœāļĨāļŠุāļ”āļ—้āļēāļĒ (MAC)

C5b-9 āđ€āļˆāļēāļ°āđ€āļĒื่āļ­āđ€āļŠื้āļ­āđ‚āļĢāļ„

C5b-9

C5b-9

āļ ูāļĄิāļ„ุ้āļĄāļัāļ™āļ—ี่āđ€āļี่āļĒāļ§āļ‚้āļ­āļ‡

Adaptive (āļ•้āļ­āļ‡āļĄี antibody)

Innate (āđƒāļŠ้ pattern sugar)

Innate (āđ„āļĄ่āļ•้āļ­āļ‡ antibody)

āļ•ัāļ§āļ­āļĒ่āļēāļ‡āđ‚āļĢāļ„āđ€āļĄื่āļ­āļ‚āļēāļ”

SLE (C1q, C2, C4), immune complex disease

Pyogenic infection early age

Recurrent Neisseria infection


🔎 āļāļĨāđ„āļāļŦāļĨัāļ 3 āļ‚ั้āļ™āļ•āļ­āļ™āļ‚āļ­āļ‡āļ—ุāļ pathway

1. Attachment (āļāļēāļĢāđ€āļāļēāļ°āļ•ิāļ”)

  • Classical: Antibody (IgM, IgG1/3) āļˆัāļš antigen āđāļĨ้āļ§ C1q āļĄāļēāļˆัāļš Fc
  • Lectin: MBL (mannose-binding lectin) āļŦāļĢืāļ­ ficolin āļˆัāļšāļ™้āļģāļ•āļēāļĨ (mannose, GlcNAc) āļšāļ™āļœิāļ§āđ€āļŠื้āļ­
  • Alternative: C3 auto-activated C3b āđ€āļāļēāļ°āļœิāļ§āđ€āļŠื้āļ­āđ‚āļ”āļĒāļ•āļĢāļ‡

2. Activation & Amplification (āļāļēāļĢāļ‚āļĒāļēāļĒāļŠัāļāļāļēāļ“)

  • āđ€āļิāļ” C3 convertase āļ•ัāļ” C3 āđ„āļ”้ C3a (anaphylatoxin) + C3b (opsonin)
  • C3b āđ€āļžิ่āļĄāļˆāļģāļ™āļ§āļ™āļĄāļēāļāđāļĨāļ°āļŠāļĢ้āļēāļ‡ “positive feedback loop” āđ‚āļ”āļĒ alternative pathway

🧠 āđ€āļ›āļĢีāļĒāļšāđ€āļ—ีāļĒāļš: āļ„āļĨ้āļēāļĒ “āļ›ืāļ™āļāļĨ” — āļĒิāļ‡āđāļĨ้āļ§āļāļĢāļ°āļŠุāļ™āđ€āļžิ่āļĄāļ‚ึ้āļ™āđ€āļ­āļ‡āđ€āļĢื่āļ­āļĒāđ†

3. Attack (Membrane Attack Complex; MAC)

  • C5 convertase āļ•ัāļ” C5 āđ„āļ”้ C5a (inflammatory peptide) + C5b (āđ€āļĢิ่āļĄāļŠāļĢ้āļēāļ‡āļĢู)
  • C5b + C6 + C7 + C8 + C9 C5b-9 pore āđ€āļˆāļēāļ°āļœāļ™ัāļ‡āđāļšāļ„āļ—ีāđ€āļĢีāļĒāđƒāļŦ้āđāļ•āļ

ðŸ’Ģ āđ€āļ›āļĢีāļĒāļšāđ€āļ—ีāļĒāļš: āđ€āļŦāļĄืāļ­āļ™ “āļŦāļ™่āļ§āļĒāļĢāļ°āđ€āļšิāļ”āđ€āļˆāļēāļ°āļ›āļĢāļ°āļ•ู” (C9 = āļ—่āļ­āļĢāļ°āđ€āļšิāļ”)


ðŸ’Ą āļ•ัāļ§āļ­āļĒ่āļēāļ‡āļāļēāļĢāđƒāļŠ้āļāļĨāđ„āļāđƒāļ™āļ„āļĨิāļ™ิāļ

āļāļĨāđ„āļāđ€āļŠีāļĒ

āļœāļĨāļ—āļēāļ‡āļ„āļĨิāļ™ิāļ

āļāļēāļĢāļ•āļĢāļ§āļˆāļ—ี่āđƒāļŠ้

C1q / C2 / C4 deficiency

SLE, immune complex disease

CH50 āļ•่āļģ āđāļ•่ AH50 āļ›āļāļ•ิ

Factor B / D / Properdin deficiency

Recurrent Neisseria infection

AH50 āļ•่āļģ āđāļ•่ CH50 āļ›āļāļ•ิ

C3 deficiency

Pyogenic infection āļĢุāļ™āđāļĢāļ‡, immune complex disease

CH50 āđāļĨāļ° AH50 āļ•่āļģāļ—ั้āļ‡āļ„ู่

Terminal C5–C9 deficiency

Meningococcal infection āļ‹้āļģ

CH50 āļĻูāļ™āļĒ์ āđāļ•่ AH50 āļ›āļāļ•ิ

C1 inhibitor deficiency

Hereditary angioedema

C4 āļ•่āļģ, C1INH function āļ•่āļģ


🧎 āļ™āļ­āļāđ€āļŦāļ™ืāļ­āļˆāļēāļ 3 pathway (āđ€āļžิ่āļĄāđ€āļ•ิāļĄ)

  • CRP pathway – C-reactive protein āļˆัāļš C1 activate classical pathway
  • Protease activation (trypsin, thrombin, kallikrein)āļ•ัāļ” C3/C5 āđ‚āļ”āļĒāļ•āļĢāļ‡ (local inflammation)
  • Intracellular complement (“complosome”) – complement āļ—āļģāļ‡āļēāļ™āđƒāļ™āđ€āļ‹āļĨāļĨ์āđ€āļ­āļ‡ āļ„āļ§āļšāļ„ุāļĄ metabolism, autophagy, gene expression
  • Bypass pathwayāļāļĢāļ“ีāļ‚āļēāļ” C4/C2 alternative pathway āļŠ่āļ§āļĒāđ„āļ”้āļšāļēāļ‡āļŠ่āļ§āļ™āđāļ•่āđ€āļŠี่āļĒāļ‡ autoimmunity

🧠 āļˆāļģāļ‡่āļēāļĒāđāļšāļšāđ€āļ›āļĢีāļĒāļšāđ€āļ—ีāļĒāļš

āđ€āļ›āļĢีāļĒāļšāđ€āļ—ีāļĒāļš

Classical

Lectin

Alternative

āđƒāļ„āļĢāđ€āļĢีāļĒāļāđƒāļŠ้āļĢāļ°āļšāļš

Antibody (IgM/IgG1,3)

Lectin (MBL, ficolin)

C3 auto-activate āđ€āļ­āļ‡

āļŠัāļāļāļēāļ“āđ€āļĢิ่āļĄāļ•้āļ™

“Antigen–antibody complex”

āļ™้āļģāļ•āļēāļĨāđāļ›āļĨāļāļšāļ™āļœิāļ§āđ€āļŠื้āļ­”

āļœิāļ§āđ€āļŠื้āļ­āđ€āļ›āļĨืāļ­āļĒ āđ„āļĄ่āļĄี self marker”

āļ„āļ§āļēāļĄāđ€āļĢ็āļ§āļ•āļ­āļšāļŠāļ™āļ­āļ‡

āļŠ้āļēāļāļ§่āļē (āļ•้āļ­āļ‡āļĄี antibody)

āđ€āļĢ็āļ§ (innate)

āđ€āļĢ็āļ§āļ—ี่āļŠุāļ” (āļ•āļĨāļ­āļ”āđ€āļ§āļĨāļē)

āļˆุāļ”āļĢ่āļ§āļĄāļัāļ™

C3b opsonization C5b–9 MAC

āļˆุāļ”āđ€āļ”่āļ™

āđ€āļŠื่āļ­āļĄ innate adaptive

āļˆāļ”āļˆāļģ pattern sugar

Amplification loop

āļ–้āļēāđ€āļŠีāļĒ

SLE, immune complex disease

Infection early infancy

Neisseria infection


🧭 āļāļēāļĢāļ•āļĢāļ§āļˆāļ—āļēāļ‡āļŦ้āļ­āļ‡āļ›āļิāļšัāļ•ิāļāļēāļĢ

1.       CH50 (classical pathway screen)

o   āļ–้āļēāļĻูāļ™āļĒ์ āļ‚āļēāļ” C1–C9 āļŦāļĢืāļ­ consume āļŦāļĄāļ”

2.       AH50 (alternative pathway screen)

o   āļ–้āļēāļ•่āļģ āļ‚āļēāļ” factor B, D, properdin

3.       C3, C4 level

o   C3 āļ•่āļģāđ€āļ”ี่āļĒāļ§ infection, alternative activation

o   C4 āļ•่āļģāđ€āļ”ี่āļĒāļ§ classical activation (immune complex, SLE)

o   C3+C4 āļ•่āļģ complement consumption

4.       C1 inhibitor function Hereditary angioedema


ðŸ§Đ āļŠāļĢุāļ›āļāļĨāđ„āļāļŠั้āļ™āđ†

“Complement = āļĢāļ°āļšāļšāļĢāļ°āđ€āļšิāļ”āļ­ัāļ•āđ‚āļ™āļĄัāļ•ิāļ‚āļ­āļ‡āļĢ่āļēāļ‡āļāļēāļĒ”

1.       āļˆัāļšāđ€āļ›้āļē (Attachment) Antibody, sugar āļŦāļĢืāļ­ C3 tickover

2.       āļ‚āļĒāļēāļĒāļŠัāļāļāļēāļ“ (Amplification) āļ•ัāļ” C3/C5 āļ›āļĨ่āļ­āļĒ C3a, C5a āļ”ึāļ‡āļ—āļŦāļēāļĢ

3.       āđ‚āļˆāļĄāļ•ี (Attack) C5b–9 MAC āđ€āļˆāļēāļ°āļĢูāđ€āļŠื้āļ­āđ‚āļĢāļ„

4.       āļ„āļ§āļšāļ„ุāļĄ (Regulation) āļ›้āļ­āļ‡āļัāļ™ host cell āđ‚āļ”āļ™āļĨูāļāļŦāļĨāļ‡ (C1-INH, DAF, CD59)


Complement: What matters clinically

āđ€āļ—āļ„āļ™ิāļ„āļŠāļģāļ„ัāļ (āļŦāļĨุāļĄāļžāļĢāļēāļ‡)

  • Specimen handling: āļ—āļģ/āđāļŠ่āđāļ‚็āļ‡ “āļ—ัāļ™āļ—ี” āļĄิāļ‰āļ°āļ™ั้āļ™ CH50 āļˆāļ°āļ›āļĨāļ­āļĄāļ§่āļēāļ•่āļģ
  • Cold activation (cryoglobulins/immune complexes) CH50 āļ•่āļģāļĄāļēāļāđāļ•่ C3/C4 āđ„āļĄ่āđ„āļ”้āļ•่āļģāļ•āļēāļĄ
  • Acute-phase: C3/C4/CH50 āļ­āļēāļˆāļŠูāļ‡ 30–50% āđƒāļ™āļāļēāļĢāļ­ัāļāđ€āļŠāļšāđ€āļ‰ีāļĒāļšāļžāļĨัāļ™ āļĢāļ°āļ§ัāļ‡āļ•ีāļ„āļ§āļēāļĄāđ€āļิāļ™āļˆāļĢิāļ‡
  • āļ—āļēāļĢāļ/āļ„āļĨāļ­āļ”āļ่āļ­āļ™āļāļģāļŦāļ™āļ”: CH50/AH50, C3/C4 āļ•่āļģāļāļ§่āļēāļœู้āđƒāļŦāļ่āđ‚āļ”āļĒāļ˜āļĢāļĢāļĄāļŠāļēāļ•ิ (āļ„่āļ­āļĒāđ† āļ›āļāļ•ิāļ—ี่ 6–18 āđ€āļ”ืāļ­āļ™)

āđ‚āļĢāļ„āđ€āļ”่āļ™āļัāļšāļŠิ้āļ™āļŠ่āļ§āļ™āļ—ี่āđ€āļŠีāļĒ (āļˆāļģāđ€āļ›็āļ™āļ„āļĨิāļ™ิāļ)

  • C1q/C2/C4 āļ•่āļģ (āļ„āļĨāļēāļŠāļŠิāļ): SLE, immune-complex disease
  • C3 deficiency: pyogenic infection āļĢุāļ™āđāļĢāļ‡ + immune complex disease
  • Terminal C5–C9: Meningococcal infection āļ‹้āļģ (CH50, AH50 āļ•่āļģ)
  • Properdin (X-linked) / Factor B/D: Neisseria; AH50 āļ•่āļģ, CH50 āļ›āļāļ•ิ
  • C1-INH deficiency (HAE): C4 āļ•่āļģ, C3 āļ›āļāļ•ิ, C1-INH func/level āļ•่āļģ
  • Alternative dysregulation (Factor H/I/MCP/C3/FB variants): aHUS, C3G/MPGN, C3 āļĄัāļāļ•่āļģ

Clinical pearls (āđƒāļŠ้āļ‡āļēāļ™āļˆāļĢิāļ‡)

  • SLE flare: C4 āļĄัāļāļĨāļ‡āļ่āļ­āļ™ (baseline C3 āļŠูāļ‡āļāļ§่āļē āļˆึāļ‡āļ­āļēāļˆāļĒัāļ‡ “āļ”ูāļ›āļāļ•ิ”) āļ•ิāļ”āļ•āļēāļĄ āđāļ™āļ§āđ‚āļ™้āļĄ āļĄāļēāļāļāļ§่āļēāļ„่āļēāđ€āļ”ีāļĒāļ§
  • HAE: āļ„ิāļ”āļ—ัāļ™āļ—ีāđ€āļĄื่āļ­ angioedema āđ„āļĄ่āļĄีāļĨāļĄāļžิāļĐ + C4 āļ•่āļģ (āļĢāļ°āļŦāļ§่āļēāļ‡/āļ™āļ­āļāļŠัāļāļ็āļ•่āļģ)
  • Neisseria āļ‹้āļģāđƒāļ™āļŠāļēāļĒ: āļ­āļĒ่āļēāļĨืāļĄ Properdin (X-linked)
  • āļ–ึāļ‡ CH50/AH50 āļ›āļāļ•ิ āļ็āļĒัāļ‡āļĄี “activation āđ€āļ‰āļžāļēāļ°āļ—ี่” āđ„āļ”้ (āđ€āļŠ่āļ™ AMD, atherosclerosis) serum āļ­āļēāļˆāđ„āļĄ่āđ€āļ›āļĨี่āļĒāļ™

Complement-based therapies (āļŠāļĢุāļ›āļ‚āļ­āļ‡āļ—ี่āļĄีāđƒāļŠ้)

  • Anti-C5: Eculizumab / Ravulizumab PNH, aHUS, āļšāļēāļ‡ DHTR; (āļ„ิāļ”āļ§ัāļ„āļ‹ีāļ™ MenACWY/MenB āļ่āļ­āļ™āđ€āļĢิ่āļĄ)
  • C3 inhibitor: Pegcetacoplan PNH
  • C5aR antagonist: Avacopan ANCA-vasculitis
  • C1-INH replacement (pd/recombinant) HAE (acute & prophylaxis)
  • āļāļģāļĨัāļ‡āļžัāļ’āļ™āļē: anti-alternative āļŠāļģāļŦāļĢัāļš AMD (intravitreal mAb)

Quick workflow (ER/OPD)

1.       āļŠāļ‡āļŠัāļĒ complement issue āļŠั่āļ‡ CH50 + C3 + C4 (āļ–้āļēāļ„ิāļ” alternative āđ€āļžิ่āļĄ AH50)

2.       CH50 āļ•่āļģ/āļĻูāļ™āļĒ์ āđ„āļ‚āđƒāļŦ้āđāļ„āļšāļ”้āļ§āļĒ C3/C4, āļžิāļˆāļēāļĢāļ“āļēāļ§ัāļ” components/regulators āđ€āļ‰āļžāļēāļ°

3.       Pattern-based Dx (āļ•āļēāļĢāļēāļ‡āļ”้āļēāļ™āļšāļ™) + āļŦāļē triggers/āđ‚āļĢāļ„āļĢ่āļ§āļĄ (SLE/cryoglobulinemia/āļāļēāļĢāļ•ิāļ”āđ€āļŠื้āļ­/procedure)

4.       āļ–้āļēāļŠี้ aHUS/C3G/Neisseria deficiency/HAE refer āļ­āļēāļĒุāļĢāđāļžāļ—āļĒ์āļ ูāļĄิāđāļž้-āļ ูāļĄิāļ„ุ้āļĄāļัāļ™/āđ„āļ•/āđ‚āļĨāļŦิāļ•āļ§ิāļ—āļĒāļēāļ•āļēāļĄāļ‚้āļ­āļš่āļ‡āļŠี้ āđāļĨāļ°āļžิāļˆāļēāļĢāļ“āļē targeted therapy


āđ„āļĄ่āļĄีāļ„āļ§āļēāļĄāļ„ิāļ”āđ€āļŦ็āļ™:

āđāļŠāļ”āļ‡āļ„āļ§āļēāļĄāļ„ิāļ”āđ€āļŦ็āļ™